[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![wegro_app Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1787088114588209152.png) Wegro App [@wegro_app](/creator/twitter/wegro_app) on x 10.2K followers
Created: 2025-06-02 02:38:17 UTC

Zydus Lifesciences received tentative approval from the USFDA for Rifaximin Tablets, XXX mg. This is for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. 💊 The tablets will be produced at the Group’s manufacturing site at SEZ II, Ahmedabad.

- 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:
  ▪ Tentative approval from USFDA for Rifaximin Tablets, XXX mg.
  ▪ Indicated for treating irritable bowel syndrome with diarrhea (IBS-D).
  ▪ Manufacturing to be done at Ahmedabad site.
  ▪ Rifaximin tablets had annual sales of USD $2672.9 million in the US (IQVIA MAT March 2025).
  ▪ The group has XXX approvals and has filed XXX ANDAs since FY 2003-04.

📊 ZYDUS LIFESCIENCES LTD | 🏷️ Press Release / Media Release

🌐 Details:

⚡️AI-driven WhatsApp updates - Try FREE 👉


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1929366935193424177/c:line.svg)

**Related Topics**
[$mngl](/topic/$mngl)
[$zyduslifebo](/topic/$zyduslifebo)

[Post Link](https://x.com/wegro_app/status/1929366935193424177)